Physician profile
Carol Roark
NPI 1669471058
$282.88
in general payments reported to CMS, 2019-2025
11 companies · $158 in 2025
The $158 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.99 · 2020: $42.94 · 2021: $42.17 · 2024: $16.69 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $174.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $70.27 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $45.91 | 2025 | Qelbree |
| Glaxosmithkline, LLC. | $26.47 | 2020 | |
| Verrica Pharmaceuticals INC. | $24.79 | 2025 | Ycanth |
| Merck Sharp & Dohme LLC | $22.53 | 2019-2021 | |
| Pfizer INC. | $17.12 | 2025 | |
| Hologic Sales and Service, LLC | $16.69 | 2024 | Thinprep 2000 Processor, Aptima |
| Lundbeck LLC | $16.47 | 2020 | |
| Lilly USA, LLC | $15.93 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.83 | 2021 | |
| Cranial Technologies, INC | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Roark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.